Some were known cancer genes, including CDKN2A, KEAP1, MYCN, PLK4, SETD2, TP53. It is possible that any of these singleton genetic changes contributed to resistance to rapalog therapy in an individual patient. The gene discussed is SETD2; the disease is cancer.